上海交通大學(xué)醫(yī)學(xué)院分子醫(yī)學(xué)研究院新建于2017年10月,，由中國科學(xué)院院士譚蔚泓教授領(lǐng)銜建立,，并依托上海交通大學(xué)醫(yī)學(xué)院附屬仁濟醫(yī)院實體建設(shè)。研究院聚焦分子醫(yī)學(xué)前沿,，立足于重大疾病創(chuàng)新藥物研發(fā)與早診確診防控技術(shù)的突破,，從基礎(chǔ)前沿研究到知識產(chǎn)權(quán)和產(chǎn)業(yè)化落地,，全程助推健康中國建設(shè)。研究院建有上海市核酸化學(xué)與納米醫(yī)學(xué)重點實驗室平臺,，并集聚多名中高水平中青年專家,。研究院已經(jīng)成為學(xué)科交叉特色鮮明的教學(xué)、科研,、產(chǎn)業(yè)化人才“搖籃”,。
研究院青年人才聚集,，提倡自由學(xué)術(shù)探索,，以學(xué)術(shù)興趣和創(chuàng)新潛力為動力,，積極鼓勵跨學(xué)科合作與創(chuàng)新。經(jīng)團隊共同建設(shè),，研究院已形成“仁愛互助”,、“快樂科研”、“爭鋒前沿”的文化氛圍,。目前,，設(shè)立有核酸化學(xué)研究組、分子自組裝與分子網(wǎng)絡(luò)研究組,、體外檢測與診斷研究組,、分子和納米藥物的臨床轉(zhuǎn)化等課題組。眾多相關(guān)成果在Nature,、Science和Nature系列等國際知名雜志上發(fā)表,。近5年團隊成員承擔(dān)有國家重大科學(xué)研究計劃、科技部重大專項,、科技部重大儀器專項,、國家杰青、優(yōu)青基金等多項國家和省部級項目,。2019年底,，經(jīng)上海市科委審批研究院正式啟動“上海市核酸化學(xué)與納米醫(yī)學(xué)重點實驗室”的建設(shè)工作。
研究院的實驗平臺布局合理,，技術(shù)力量雄厚,，儀器設(shè)備先進。配備有共聚焦掃描顯微鏡,、軌道阱質(zhì)譜儀,、核磁共振儀、透射電鏡,、原子力顯微鏡,、紫外光刻系統(tǒng)等多臺大型精密儀器。
建院以來,，研究院致力完善從基礎(chǔ)研究到應(yīng)用開發(fā)的完整創(chuàng)新成果產(chǎn)出,。已與上海市三級甲等醫(yī)療單位開展臨床合作研究，實現(xiàn)了基礎(chǔ)研究和臨床應(yīng)用的緊密結(jié)合,。
The Institute of Molecular Medicine (IMM), Shanghai Jiao Tong University School of Medicine, was established in October 2017 and led by Prof. Weihong Tan, who is academician of the Chinese Academy of Sciences. Based in Renji hospital, IMM focuses on cutting edge research of molecular medicine that aims to achieve scientific breakthrough in early diagnosis and drug innovation against major diseases, to promote the integration of basic research, intellectual property, and clinical translation, and ultimately to aid the realization of Health China. IMM, together with the Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, now has many high-level scientists. To date, IMM has become the incubator for inter-disciplinary talents devoted to teaching, research, and technique translation.
IMM, which advocate free academic exploration, has gathered many young talents. We actively encourage interdisciplinary cooperation and innovation, driven by academic interest and innovation potential. Under the joint effort of the team, the institute has formed a cultural atmosphere of "Care and mutual assistance", "Happy scientific research" and "Striving for the frontier". At present, multiple research groups have been built including nucleic acid chemistry research group, molecular self-assembly and molecular network research group, in-vitro detection and diagnosis research group, molecular and nano-drug clinical transformation research group etc. Many research achievements have been published in top-notch international journals, such as Nature, Science, and Nature research journals. PIs from IMM have been supported by many national and provincial projects during the past 5 years, including Major Program of the National Natural Science Foundation of China, National Science and Technology Major Project of the Ministry of Science and Technology of China, National Science and Technology Major Project of the Ministry of Instrument of China, The National Science Fund for Distinguished Young Scholars, National Natural Science Foundation for Outstanding Young Scholars. At the end of 2019, the Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine based in IMM was approved by the Shanghai Science and Technology Committee.
The laboratory platform of the institute provides plentiful space and advanced instruments including confocal scanning microscopy, fully functional steady-state and transient fluorescence spectrometers, fluorescence real-time quantitative thermal circulator, high throughput DNA synthesizer, gel permeation chrommatography, flow cytometry, chemiluminescence imaging system, nucleic acid fragment analyzer, gas chromatography-mass spectrography, ultra-depth of field 3d microscopic system, UV lithography system, orbital trap mass spectrometer, nuclear magnetic resonance spectrometer, transmission electron microscope, atomic force microscope etc.
Since its inception, IMM has committed to promoting innovation from basic research to clinical application. Numerous clinical cooperative research projects with Shanghai First Class Grade 3A Hospitals have been initiated to facilitate the integration of basic research and clinical applications.
